Follow this link:
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.
Related Post
- Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference - December 27th, 2024
- Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements - December 27th, 2024
- COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization - December 27th, 2024
- Neutrolis Licenses University of Illinois Chicago Patent to Advance Topical Dry Eye Disease Therapy Targeting NETs - December 27th, 2024
- Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia - December 27th, 2024
- Spectral AI Announces Confirmation of Compliance of its Nasdaq Listing Requirements - December 27th, 2024
- Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference - December 27th, 2024
- Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute - December 27th, 2024
- SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation - December 27th, 2024
- Optinose Announces 1-for-15 Reverse Stock Split - December 27th, 2024
- Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing... - December 27th, 2024
- Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in... - December 27th, 2024
- Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives - December 27th, 2024
- CORXEL Acquires Worldwide (excluding Greater China) Rights to an Oral Small Molecule GLP-1 RA for the Treatment of Obesity and Diabetes - December 25th, 2024
- HCW Biologics Inc. Received NASDAQ Staff Determination Letter - December 25th, 2024
- Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement - December 25th, 2024
- Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity - December 25th, 2024
- Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis... - December 25th, 2024
- GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds - December 25th, 2024
- RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program - December 25th, 2024
- XBiotech Pauses Rheumatology program - December 25th, 2024
- Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment - December 25th, 2024
- Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference - December 25th, 2024
- Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market - December 25th, 2024
- Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD - December 25th, 2024
- Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis - December 25th, 2024
- Abivax Announces a Change to the Composition of its Board of Directors - December 25th, 2024
- Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million - December 25th, 2024
- Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference - December 25th, 2024
- Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq - December 25th, 2024
- Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial - December 25th, 2024
- PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a... - December 25th, 2024
- Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca - December 25th, 2024
- Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics - December 22nd, 2024
- Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules - December 22nd, 2024
- Epitopea and Genevant Sciences Announce Collaboration Agreement - December 22nd, 2024
- Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma - December 22nd, 2024
- ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies - December 22nd, 2024
- Idorsia provides update on the exclusive negotiations for the global rights to aprocitentan - December 22nd, 2024
- Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy - December 22nd, 2024
- Nxera Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - December 22nd, 2024
- CancerVax Passes First Test with Flying Colors - December 22nd, 2024
- Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales - December 22nd, 2024
- Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial - December 22nd, 2024
- Applied Therapeutics Appoints John H. Johnson as Executive Chairman - December 20th, 2024
- Verrica Provides Business and Operational Update - December 20th, 2024
- ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility - December 20th, 2024
- Lowell Farms Inc. Appoints Philippe Faraut as Chief Financial Officer - December 20th, 2024
- InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 - December 20th, 2024
- Sernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025 - December 20th, 2024
- Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets - December 20th, 2024
- Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid... - December 20th, 2024
- RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial - December 20th, 2024
- Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection - December 20th, 2024
- IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank - December 20th, 2024
- Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine - December 20th, 2024
- Avextra Backs Landmark Psilocybin Therapy Study in Palliative Care - December 20th, 2024
- Syntekabio to Showcase AI-Driven Drug Discovery Solutions at Biotech Showcase 2025 - December 20th, 2024
- Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29,... - December 20th, 2024
- Renovaro Regains Compliance with NASDAQ Listing Requirement - December 20th, 2024
- Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old - December 20th, 2024
- PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement - December 20th, 2024
- Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates - December 20th, 2024
- Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) - December 20th, 2024
- ViGeneron Announces FDA Clearance of IND for Novel mRNA Trans-Splicing Gene Therapy VG801 to Treat Stargardt Disease and Other ABCA4-Linked Retinal... - December 19th, 2024
- Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies - December 19th, 2024
- Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model - December 19th, 2024
- Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor - December 19th, 2024
- Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 - December 19th, 2024
- Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology - December 19th, 2024
- Akari Therapeutics Announces Key Leadership Appointments - December 19th, 2024
- The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is... - December 19th, 2024
- Rafarma pharmaceutical updates - December 19th, 2024
- T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor - December 19th, 2024
- BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions - December 19th, 2024
- Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics - December 19th, 2024
- Longeveron to Present at Biotech Showcase 2025 - December 19th, 2024
- TigaTx Announces up to $35.5M in Funding from ARPA-H and NIH Awards to Advance First-in-Class Engineered IgA Monoclonal Antibody for Cancer and... - December 19th, 2024
- Olympia Pharmaceuticals Announces the Launch of Sister Brand, Wesley Pharmaceuticals, in Honor of Beloved Employee - December 19th, 2024
- OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO - December 19th, 2024
Recent Comments